ERC 1671

Drug Profile

ERC 1671

Alternative Names: ERC-1671; Gliovac

Latest Information Update: 07 Jan 2016

Price : $50

At a glance

  • Originator Epitopoietic Research Corporation
  • Developer Epitopoietic Research Corporation; University of California at Irvine
  • Class Antineoplastics; Brain cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Glioma

Most Recent Events

  • 07 Jan 2016 Phase-II development for Glioma/Glioblastoma (Recurrent, Combination therapy) is ongoing in USA (NCT01903330)
  • 01 Mar 2014 Phase-II clinical trials in Glioma (Recurrent, Combination therapy) in USA (Intradermal)
  • 01 Mar 2014 Phase-II clinical trials in Glioblastoma (Recurrent, Combination therapy) in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top